Article
Author(s):
Top articles of the week from The American Journal of Pharmacy Benefits.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
2 Commerce Drive
Cranbury, NJ 08512